NASH continues to be a huge unmet clinical need globally, and although no therapy has received regulatory approval, there continues to be research advancing our understanding of the disease’s mechanisms. Developments in non-invasive diagnostic biomarkers continue to offer the hope that they will replace liver biopsies and there have been improvements to in vivo liver models. All these are the focus of this year’s congress as well as new preclinical and clinical research. The most promising therapeutics in development and business case studies will also be featured at this meeting.

7 hours of networking time

30+ KOLs

Clinical readouts from late stage trials

Why Attend This Conference


Investigate how non-invasive tests may replace liver biopsy as the referent standard for the pragmatic clinical management of NAFLD


Learn how semaglutide and combination therapies can address the metabolic drivers of NASH and Explore advances in anti-obesity medications and research into the efficacy of exercise.


Attracting over 200 people the congress is designed to create a collaborative environment in which you can engage with the speakers, sponsors, and other delegations in attendance

Previous Speakers

Michelle T. Long

International Medical Vice President, NASH & Liver Diseases, Novo Nordisk, Denmark

Christopher D. Byrne

Professor of Endocrinology & Metabolism, University of Southampton, UK

Bruno Ramos Molina

Senior Researcher, Biomedical Research Institute of Murcia (IMIB), Spain

Mathias Heikenwaelder

Professor, German Cancer Research Center (DKFZ), Heidelberg and Director, The M3 Research Institute, Tuebingen, Germany

Sid Barritt

Director, UNC Liver Center, University of North Carolina, USA

Luca Miele

Professor, Fondazione Policlinico Gemelli IRCCS, Catholic University of Rome, Italy

Jonas Heilskov Graversen

Associate Professor, University of Southern Denmark, Denmark

Quin Wills

CSO, Ochre-Bio, UK

Vinood Patel

Professor in Clinical Biochemistry, University of Westminster

Andrew Fowell

Clinical Director for Gastroenterology & Hepatology, Queen Alexandra Hospital, UK

Dimitrios Koutoukidis

Senior Research Fellow, University of Oxford, UK

Sander Lefere

Postdoctoral Researcher, Ghent University, Belgium

Romain Baujard

Vice President, Pharma, Echosens, France

Jonathan Seltzer

Executive Director, Cardiovascular Safety Research Consortium, USA

Scott Harris

Chief Medical Officer, Altimmune, USA

Richard Torstenson

Director Global Regulatory Affairs, AstraZeneca

Jonathan Stine

Fatty Liver Program Director, Liver Center Research Director, Penn State Health - Milton S. Hershey Medical Center, USA

Michael P. Cooreman

Chief Medical Officer, Inventiva

Ezra Lowe

Executive Director of Clinical and Preclinical Pharmacology, Galectin Therapeutics, USA

Volker M. Lauschke

Professor, Karolinska Institutet, Bosch Institute of Clinical Pharmacology, Sweden

Radha Krishnan

Executive Director, Clinical Pathology Lead, MSD, UK

Reiko Matsui

Assistant Professor, Boston University, USA

Jeff Mcintyre

Vice-President, Liver Health Programs, Global Liver Institute, USA

Aldo Trylensinski

Executive Director, Advanz Pharma

Todd Hobbs

Chief Medical Officer, Hepion Pharmaceuticals, USA

Gabriele Mocciaro

Postdoctoral Scientist, The Roger WiIliams Institute of Hepatology, UK

Santo Colosimo

Clinical Research Fellow, University of Oxford, UK

Steve Williams

Chief Medical Officer, SomaLogic, USA

Anja Geerts

Associate Professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium

Lopa Mishra

Merinoff Endowed Chair and Professor of Medicine, The Feinstein Institutes for Medical Research (Northwell Health) and Cold Spring Harbor Laboratory

Mojgan Masoodi

Associate Professor & Head of Research, Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Switzerland

Ramy Younes

Senior Corporate Clinical Program Leader, Boehringer Ingelheim

Christopher Shepard

Venture Partner, Apollo Health Ventures, USA

Rebecca Taub

Chief Medical Officer, President of Research & Development, Madrigal Pharmaceuticals

Manuel Castro Cabezas

Scientific Officer, Julius Clinical

Hamish Miller

Clinical Research Fellow and PhD Student, Oxford University & Queen Mary University of London

Juergen Eckel

CEO, CureDiab Metabolic Research GmbH

Rutger Fick

Senior AI Lead, Tribun Health

Francisco Verdeguer

VP, Liver Disovery, Insphero

Diana Chung

Chief Development Officer, Terns Pharmaceuticals, USA

Load more

Our Sponsor


Our Commitment to Sustainability

Global Engage is a member of ISLA, a body established to accelerate the event industry transition to a sustainable future. We have reduced waste by replacing printed documentation with an app. Make sure you have it downloaded to your devices in time for the meeting.

You will have some great food choices while you are with us but now we have increased the proportion of plant-based items. We have also built a plan with the venue to avoid waste through how meals are served. Please consider more sustainable alternatives to flying. The app will also have a discussion space to arrange ride shares.

Meet Your Next Big Client – Sponsor An Event

Sponsors and exhibitors at our conferences have the opportunity to meet and form partnerships with delegates on a formal and informal basis in a relaxed and professional atmosphere.